Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
nucleotide-binding domain
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "nucleotide-binding domain" in MCE Product Catalog:
12
12 Cited Publications
Target:
Research Areas:
GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells .
8
8 Cited Publications
Target:
Research Areas:
NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.
Synonyms: (R)-VX-445
Target:
Research Areas:
(R)-Elexacaftor ((R)-VX-445) is the enantiomer of Elexacaftor (HY-111772). Elexacaftor is an orally active CFTR modulator that targets nucleotide-binding domain 1. Elexacaftor stabilizes misfolded F508del-CFTR protein, enhances its trafficking to the plasma membrane, and significantly improves metabolic stability, thermal stability and ion conductivity. Elexacaftor not only restores chloride transport function in nasal epithelial cells and rescues multiple CFTR mutation subtypes, but also exerts multiplicative synergistic effects with Ivacaftor (HY-13017), and is often used in a triple combination therapy with Tezacaftor (HY-15448). Elexacaftor is widely used in basic and clinical translational research on cystic fibrosis .
Cat. No.: HY-175278
Target:
Research Areas:
BAL-1516 is an orally active NLRP3 inhibitor with human NLRP3 Kd of 14.2 nM, mouse NLRP3 Kd of 200 nM, and blood-brain barrier penetration.BAL-1516 binds to a surface groove of the NLRP3 nucleotide-binding domain, contacts FISNA and WHD subdomains, forms three hydrogen bonds to the peripheral β-strand of the triple-ATPase, and does not alter NLRP3 ATP-hydrolysis activity.BAL-1516 shows specificity for NLRP3 over other NOD-like receptors, directly binds mouse NLRP3, and inhibits inflammasome formation in monocytes and microglia .
Cat. No.: HY-119229
CAS No.: 815592-21-3
Target:
Research Areas:
VRT-325 is a CFTR modulator. VRT-325 inhibits disulfide cross-linking between cysteines in transmembrane segments 6 and 7 of CFTR and P-gp. VRT-325 promotes maturation of CFTR and P-gp processing mutants, rescues ΔF508-CFTR folding at the endoplasmic reticulum. VRT-325 binds ΔF508-CFTR nucleotide-binding domain 1, and increases mature ΔF508-CFTR cell surface expression and chloride conductance. VRT-325 can be used for the research of cystic fibrosis [1] [3].
Cat. No.: HY-146034
CAS No.: 2704623-69-6
Target:
Research Areas:
NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding
oligomerization domain-like receptor 1/2) dual antagonist, with IC50 values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .
Cat. No.: HY-145416
G247 is a specific MsbA inhibitor. G247 acts as a transmembrane domains (TMDs) wedge, symmetrically increasing nucleotide-binding domains (NBDs) separation and preventing conformational transition of MsbA. G247 suppresses ATPase activity by increasing inter-NBD distance .
Cat. No.: HY-168159
Research Areas:
TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC50 of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC50 of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic .
Cat. No.: HY-171592
CAS No.: 2789711-40-4
Research Areas:
RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) .
Cat. No.: HY-131776
CAS No.: 16506-88-0
Synonyms: 2-Chloroadenosine 5′-diphosphate
Target:
Research Areas:
2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sis a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase . 2-Chloro-ADP inhibits mortalin nucleotide-binding domain (NBD) with a Ki of 45.05 μM .
Cat. No.: HY-131776A
CAS No.: 82927-78-4
Synonyms: 2-Chloroadenosine 5′-diphosphate sodium solution (10 mM)
Target:
Research Areas:
2-Chloro-ADP (2-Chloroadenosine 5′-diphosphate) sodium (10 mM) is a Adenosine 5'-diphosphate (ADP; HY-W010918) derivative that induces human platelet aggregation and inhibits stimulated adenylate cyclase . 2-Chloro-ADP sodium (10 mM) inhibits mortalin nucleotide-binding domain (NBD) with a Ki of 45.05 μM .
Cat. No.: HY-181810
CAS No.: 2215779-34-1
EG36 is a selective E. coli DnaK inhibitor that inhibits DnaK ATPase activity at a concentration of 100 μM. EG36 directly binds to the nucleotide-binding domain (NBD) of E. coli DnaK by disrupting the DnaK-DnaJ interaction. EG36 can be used for research on bacterial infectious diseases .
Cat. No.: HY-P703357
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NOD2; Caspase Recruitment domain Family, Member 15; Prev. CARD15; Inflammatory Bowel Disease Protein 1; Prev. IBD1; NOD-Like Receptor C2; nucleotide-binding Oligomerization domain-Containing Protein 2; nucleotide-binding Oligomerization domain Containing
Species:
Source:
Cat. No.: HY-P89570
Synonyms: CARD7, DEFCAP, KIAA0926, NAC, NALP1, NLRP1, Caspase recruitment domain-containing protein 7, Death effector filament-forming ced-4-like apoptosis protein, nucleotide-binding domain and caspase recruitment domain
Cat. No.: HY-100691R
CAS No.: 132819-92-2
Research Areas:
NOD-IN-1 (Standard) is the analytical standard of NOD-IN-1 (HY-100691). This product is intended for research and analytical applications. NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.
Cat. No.: HY-P702188
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NLRP1; nucleotide-binding domain And Caspase Recruitment domain; Prev. NALP1; DKFZp586O1822; Prev. SLEV1; Systemic Lupus Erythematosus, Vitiligo-Related 1; DEFCAP; NACHT, Leucine Rich Repeat And PYD Containing 1; CARD7; NACHT, LRR And PYD Containing Prote
Cat. No.: HY-P702189
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NLRP1; nucleotide-binding domain And Caspase Recruitment domain; Prev. NALP1; DKFZp586O1822; Prev. SLEV1; Systemic Lupus Erythematosus, Vitiligo-Related 1; DEFCAP; NACHT, Leucine Rich Repeat And PYD Containing 1; CARD7; NACHT, LRR And PYD Containing Prote
Cat. No.: HY-P703410
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: NLRP9; nucleotide-binding Oligomerization domain, Leucine Rich Repeat And Pyrin domain Containing 9; Prev. NALP9; NACHT, Leucine Rich Repeat And PYD Containing 9; PAN12; NACHT, LRR And PYD domains-Containing Protein 9; NOD6; PYRIN And NACHT-Containing Pro
Species:
Source:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
